Brenig Therapeutics Presents Phase 1 BT-267,BT-409 & NLRP3
18 Mar 2026 //
PR NEWSWIRE
Mwyngil Therapeutics Announces Updates On NLRP3 Portfolio
02 Feb 2026 //
PR NEWSWIRE
Brenig Announces Initiation of First-in-Human Study of BT-409
15 Jan 2026 //
PR NEWSWIRE
Brenig Therapeutics Names Megan Mcgill as Chief Executive Officer
30 Oct 2025 //
PR NEWSWIRE

Market Place
Sourcing Support